BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34826699)

  • 21. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
    Wu WS; Chien CC; Chen YC; Chiu WT
    PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
    Ruan H; Li S; Bao L; Zhang X
    Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
    Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
    Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
    Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
    Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PON1 hypermethylation is associated with progression of renal cell carcinoma.
    Li X; Yu Q
    J Cell Mol Med; 2019 Oct; 23(10):6646-6657. PubMed ID: 31400051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
    Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
    PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
    Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
    Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
    Jiang XL; Zhang Y; Luo CL; Wu XH
    Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
    Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
    Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.